Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Enzalutamide-ADT a win for biochemically recurrent prostate cancer
27 Oct 2025
bởiAudrey Abella
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.








